GSK2801 is primarily used as a selective inhibitor of bromodomain-containing proteins, particularly targeting the BET (bromodomain and extra-terminal) family. It is widely applied in epigenetic research to modulate gene expression by blocking the interaction between bromodomains and acetylated histones. This activity makes it a valuable tool in studying cancer cell proliferation, inflammation, and viral latency. In oncology research, GSK2801 demonstrates potential in suppressing the growth of certain tumor types by downregulating oncogenes such as MYC. It is also used in studies related to immune regulation and inflammatory diseases due to its ability to inhibit pro-inflammatory gene pathways. Additionally, GSK2801 has been employed in virology to investigate reactivation mechanisms of latent HIV, offering insights into potential cure strategies. Its specificity and cell permeability make it suitable for in vitro and in vivo experimental models, supporting drug discovery and mechanistic studies in epigenetics.